|
2024 Journal Article Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 TrialAnnageldiyev, Charyguly, Gaudreau, Pierre-Olivier, Leitzel, Kim, Ali, Suhail M., Ding, Keyue, Leighl, Natasha B., Vera Badillo, Francisco Emilio, Bradbury, Penelope Ann, Goss, Glenwood D., Shepherd, Lois E., Costa, Luis, Suva, Larry J., Hughes, Brett G.M., Stockler, Martin R., Drabick, Joseph J., Ma, Patrick C., Joshi, Monika, Moku, Prashanth, Polimera, Hyma V., Louis, Patricia, Ramachandrula, Priya and Lipton, Allan (2024). Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial. JCO Oncology Advances (1). doi: 10.1200/oa.24.00017 |
|
2024 Journal Article Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy responseSadeghirad, Habib, Monkman, James, Tan, Chin Wee, Liu, Ning, Yunis, Joseph, Donovan, Meg L., Moradi, Afshin, Jhaveri, Niyati, Perry, Chris, Adams, Mark N., O’Byrne, Ken, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. Journal of Translational Medicine, 22 (1) 677, 677. doi: 10.1186/s12967-024-05409-y |
|
2024 Journal Article A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinomaLadwa, Rahul, Chandra, Janin, Woo, Wai-Ping, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Xu, Yan, Panizza, Benedict, Frazer, Ian and Porceddu, Sandro V. (2024). A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Frontiers in Oncology, 14 1419258, 1-8. doi: 10.3389/fonc.2024.1419258 |
|
2024 Journal Article Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trialSolomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven and Bauer, Todd M. (2024). Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trial. JTO Clinical and Research Reports, 5 (7) 100685. doi: 10.1016/j.jtocrr.2024.100685 |
|
2024 Journal Article Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyCho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Wilson H., Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F. and Hughes, Brett G. M. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer, 23 (Suppl 1) 1254, 1-12. doi: 10.1186/s12885-023-11316-0 |
|
2024 Journal Article Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancerFelip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G. M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I. and Cobo, Manuel (2024). Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer. Lung Cancer, 192 107820, 107820. doi: 10.1016/j.lungcan.2024.107820 |
|
2024 Journal Article Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialMachiels, Jean-Pascal, Tao, Yungan, Licitra, Lisa, Burtness, Barbara, Tahara, Makoto, Rischin, Danny, Alves, Gustavo, Lima, Iane Pinto Figueiredo, Hughes, Brett G M, Pointreau, Yoann, Aksoy, Sercan, Laban, Simon, Greil, Richard, Burian, Martin, Hetnał, Marcin, Delord, Jean-Pierre, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, Bidadi, Behzad, Siu, Lillian L, Hughes, Brett GM, Gao, Bo ... Obara, Grzegorz S (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 25 (5), 572-587. doi: 10.1016/S1470-2045(24)00100-1 |
|
2024 Journal Article Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in QueenslandPorceddu, Sandro, Negrello, Theresa, Rawson, Neal, Dunn, Nathan, Batstone, Martin, Collins, Michael, Dowthwaite, Sam, Hughes, Brett G. M., Kenny, Liz, Ladwa, Rahul, Panizza, Ben and Cossio, Danica (2024). Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. Journal of Medical Imaging and Radiation Oncology, 68 (4), 472-480. doi: 10.1111/1754-9485.13643 |
|
2024 Journal Article High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaRischin, Danny, Hughes, Brett G. M., Basset-Séguin, Nicole, Schadendorf, Dirk, Bowyer, Samantha, Trabelsi Messai, Sabiha, Meier, Friedegund, Eigentler, Thomas K, Casado Echarren, Victoria, Stein, Brian, Beylot-Barry, Marie, Dalac, Sophie, Dréno, Brigitte, Migden, Michael R, Hauschild, Axel, Schmults, Chrysalyne D, Lim, Annette M, Yoo, Suk-Young, Paccaly, Anne J, Papachristos, Apostolos, Nguyen, Jenny-Hoa, Okoye, Emmanuel, Seebach, Frank, Booth, Jocelyn, Lowy, Israel, Fury, Matthew G and Guminski, Alexander (2024). High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 12 (3) e008325, 1-8. doi: 10.1136/jitc-2023-008325 |
|
2024 Journal Article Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programmeAlexander, Marliese, Rogers, Jennifer, Parakh, Sagun, Mitchell, Paul, Clay, Timothy D., Kao, Steven, Hughes, Brett G. M., Itchins, Malinda, Kong, Benjamin Y., Pavlakis, Nick, Solomon, Benjamin J. and John, Thomas (2024). Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. Internal Medicine Journal, 54 (7), 1087-1096. doi: 10.1111/imj.16348 |
|
2024 Journal Article Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapyBlake, Claire, Lai, Rainbow, Brown, Teresa, Pelecanos, Anita, Moroney, Laura, Helios, Jennifer, Smith, David, Hughes, Brett G. M., Kenny, Lizbeth, Chua, Benjamin and Bauer, Judith (2024). Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics, 37 (1), 182-192. doi: 10.1111/jhn.13243 |
|
2024 Journal Article Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyMcLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona and Rischin, Danny (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220 (2), 80-90. doi: 10.5694/mja2.52199 |
|
2023 Journal Article Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2023). Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Dermatology and Therapy, 13 (12), 3165-3180. doi: 10.1007/s13555-023-01059-y |
|
2023 Journal Article Development and validation of txSim: A model of advanced lung cancer treatment in AustraliaNgo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen and Weber, Marianne (2023). Development and validation of txSim: A model of advanced lung cancer treatment in Australia. PharmacoEconomics, 41 (11), 1525-1537. doi: 10.1007/s40273-023-01291-6 |
|
2023 Journal Article A tailored approach to horizon scanning for cancer medicinesSoon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J. ... IJzerman, Maarten (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38 100441, 1-8. doi: 10.1016/j.jcpo.2023.100441 |
|
2023 Journal Article Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyGross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo Bernard, Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G. M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Yoo, Suk-Young, Mathias, Melissa, Han, Hyunsil, Seebach, Frank, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2023). Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet Oncology, 24 (11), 1196-1205. doi: 10.1016/S1470-2045(23)00459-X |
|
2023 Journal Article Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironmentJhaveri, Niyati, Ben Cheikh, Bassem, Nikulina, Nadezhda, Ma, Ning, Klymyshyn, Dmytro, DeRosa, James, Mihani, Ritu, Pratapa, Aditya, Kassim, Yasmin, Bommakanti, Sidharth, Shang, Olive, Berry, Shannon, Ihley, Nicholas, McLane, Michael, He, Yan, Zheng, Yi, Monkman, James, Cooper, Caroline, O'Byrne, Ken, Anand, Bhaskar, Prater, Michael, Basu, Subham, Hughes, Brett G. M., Kulasinghe, Arutha and Braubach, Oliver (2023). Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment. GEN Biotechnology, 2 (5), 418-434. doi: 10.1089/genbio.2023.0029 |
|
2023 Journal Article Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapySadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N., Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O’Byrne, Ken, Davis, Melissa, Hughes, Brett G. M. and Kulasinghe, Arutha (2023). Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. Frontiers in Immunology, 14 1135489, 1-16. doi: 10.3389/fimmu.2023.1135489 |
|
2023 Journal Article LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancerAlexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett G. M., Clay, Timothy D., Pavlakis, Nick, Solomon, Benjamin J. and Itchins, Malinda (2023). LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer. JTO Clinical and Research Reports, 4 (4) 100490, 1-13. doi: 10.1016/j.jtocrr.2023.100490 |
|
2023 Journal Article Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/dayTaylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran and Brose, Marcia S. (2023). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine, 12 (4), 4332-4342. doi: 10.1002/cam4.5308 |
